AlphAIalphai — Financial news for AI agents
ibtimes.com.auAUG 192 min read$MRNA

Moderna Shares Skyrocket Up to 90% as Its mRNA Cancer Vaccine With Merck Succeeds in Late-Stage Trial

Moderna (MRNA) and Merck (MRK) announced positive late-stage trial results for their mRNA cancer vaccine, intismeran autogene, combined with Merck's Keytruda. The trial met primary and key secondary goals, showing significant improvement in melanoma treatment. Moderna's shares surged up to 90% in premarket trading, while Merck's shares climbed over 8%. The companies plan to present full results at an upcoming medical conference and share data with regulators.

Original reporting
ibtimes.com.au
Published Aug 19, 2026, 1:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 1:22 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Moderna Shares Skyrocket Up to 90% as Its mRNA Cancer Vaccine With Merck Succeeds in Late-Stage Trial — source image
Source · ibtimes.com.au
Decision brief

The 30-second read

$MRNABullishHigh
01

Why it matters

The trial’s success validates the personalized vaccine model, potentially opening a multi‑billion revenue stream.

02

Market read

First‑time disclosure of pivotal Phase 3 data drives sharp price moves and may reshape oncology investment theses.

03

What to watch

Pending overall survival data and FDA review timeline could limit near‑term upside.

Relevance 9/10Novelty 9/10Timing: premarket Wednesday

Background

Moderna’s mRNA platform expands from COVID‑19 vaccines to personalized cancer therapy, partnering with Merck.

Company-level read

Ticker impact

$MRNABullishHigh confidence
Context

Moderna announced its Phase 3 melanoma vaccine succeeded, driving a 90% pre‑market surge.

Expected impact

Further upside on trial validation, but volatility expected on regulatory milestones.

Evidence & confidence

First‑time disclosure of pivotal trial data for a small‑cap biotech; market reaction already strong.

$MRKBullishMedium confidence
Context

Merck’s share price rose >8% after its partner Moderna’s successful melanoma vaccine trial.

Expected impact

Limited upside relative to size; potential catalyst for future oncology earnings.

Evidence & confidence

Large cap; trial success benefits portfolio but impact diluted by scale.

Market effects

Sector

Boosts confidence in mRNA oncology approaches, may lift biotech sector.

Regional

U.S. biotech and pharma stocks could see spillover gains.

Global

Highlights US‑based mRNA innovation, relevant for global oncology investors.

Counterpoint

What could challenge this read

High valuation risk if later data temper efficacy or safety; regulatory delays could reverse gains.

Key entities

  • company
    Moderna

    Biotech firm developing mRNA therapeutics.

  • company
    Merck

    Pharmaceutical giant co‑developing the melanoma vaccine.

Read at source← All news

Also covered by

1 outlet

Related articles

AUG 20
$MRNAMedAI 9/10

From COVID to cancer: How Moderna’s stock jumped 177% in a day

Moderna's stock surged 177% after announcing positive clinical trial results for an experimental cancer vaccine developed with Merck. The vaccine, using mRNA technology, extended recurrence time in melanoma patients. Moderna's stock later fell 24% to $133.32. Analysts see cancer as a significant growth opportunity for Moderna, despite past challenges and political headwinds.

inquirer.com3 min
AUG 20
HighAI 8/10

Samyang Biopharm Hits Limit-Up as Moderna-MSD Cancer Vaccine Data Spark mRNA Rally [K-Bio Pulse]

Samyang Biopharm's stock surged to its daily limit after Moderna and Merck & Co. reported positive Phase 3 results for their mRNA cancer vaccine. Samyang also disclosed preclinical data for its mRNA delivery platform, NanoReady, which showed promising results in non-human primates. Other South Korean biotech stocks with mRNA or oncology ties also saw significant gains.

edaily.co.kr2 min
AUG 20
$MRNAHighAI 9/10

Armenian-American Noubar Afeyan’s Moderna soars after breakthrough cancer vaccine results

Moderna (MRNA) and Merck (MRK) reported positive Phase 3 trial results for their personalized cancer vaccine, intismeran autogene, showing longer cancer-free periods in melanoma patients. Shares of both companies surged. The vaccine uses mRNA technology and is tailored to individual tumor mutations. Detailed data and overall survival results are pending. Moderna co-founder Noubar Afeyan is an Armenian-American scientist and entrepreneur.

horizonweekly.ca2 min
AUG 20
$MRKHighAI 9/10

Merck and Moderna announce positive results for mRNA vaccine against skin cancer

Merck (MRK) and Moderna (MRNA) reported positive phase 3 trial results for an mRNA-based skin cancer treatment, called autogenous intismeran, combined with Merck's Keytruda. The therapy showed a statistically significant improvement in relapse-free survival for advanced melanoma patients post-surgery. Moderna shares rose over 2.5x, adding $40B to its market cap, while Merck shares increased over 12%. Full data will be presented at a medical congress, and regulatory approval processes will follow

bursa.ro2 min
AUG 20
$MRNAMedAI 8/10

Moderna's cancer vaccine hits key goal in melanoma trial with NYU Langone link

Moderna and Merck reported positive late-stage trial results for their personalized cancer vaccine, which, when combined with Merck's Keytruda, showed improved outcomes in melanoma patients compared to Keytruda alone. The trial included one patient from NYU Langone Hospital. Moderna's stock surged after the announcement, rising from $62.96 to $174.38, though it later gave back some gains. Merck's stock also increased. The companies plan to present the data at an upcoming medical meeting and shar

newsday.com3 min